http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 27 Aug 2026 18:45:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Aug+26++Filed+by%3A+WELTERS+ANTHONY/26991599.html si-local-file:///var/storage/secattach/20260827/26991599.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Aug+26++Filed+by%3A+WELTERS+ANTHONY/26991599.html Thu, 27 Aug 2026 18:45:00 -0400 GILD O.00092067 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Aug+26++Filed+by%3A+WELTERS+ANTHONY/26991599.html si-local-file:///var/storage/secattach/20260827/26991599.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++GILEAD+SCIENCES%2C+INC.+++++For%3A+Aug+26++Filed+by%3A+WELTERS+ANTHONY/26991599.html Thu, 27 Aug 2026 18:45:00 -0400 GILD O.00092067 http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 in adults who are virologically suppressed.</p> <p>According to a company press release, Bixlenvo is described as the first STR option for virologically suppressed adults on complex HIV treatment regimens who are unable to take currently available STRs. The tablet combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor that the company says has no cross-resistance to other existing antiretrovirals. The combination of bictegravir and lenacapavir is not http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html Thu, 27 Aug 2026 17:47:22 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 in adults who are virologically suppressed.</p> <p>According to a company press release, Bixlenvo is described as the first STR option for virologically suppressed adults on complex HIV treatment regimens who are unable to take currently available STRs. The tablet combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor that the company says has no cross-resistance to other existing antiretrovirals. The combination of bictegravir and lenacapavir is not http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html Thu, 27 Aug 2026 17:47:22 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 in adults who are virologically suppressed.</p> <p>According to a company press release, Bixlenvo is described as the first STR option for virologically suppressed adults on complex HIV treatment regimens who are unable to take currently available STRs. The tablet combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor that the company says has no cross-resistance to other existing antiretrovirals. The combination of bictegravir and lenacapavir is not http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html Thu, 27 Aug 2026 17:47:22 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 in adults who are virologically suppressed.</p> <p>According to a company press release, Bixlenvo is described as the first STR option for virologically suppressed adults on complex HIV treatment regimens who are unable to take currently available STRs. The tablet combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor that the company says has no cross-resistance to other existing antiretrovirals. The combination of bictegravir and lenacapavir is not http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html Thu, 27 Aug 2026 17:47:22 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 in adults who are virologically suppressed.</p> <p>According to a company press release, Bixlenvo is described as the first STR option for virologically suppressed adults on complex HIV treatment regimens who are unable to take currently available STRs. The tablet combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor that the company says has no cross-resistance to other existing antiretrovirals. The combination of bictegravir and lenacapavir is not http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html Thu, 27 Aug 2026 17:47:22 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 in adults who are virologically suppressed.</p> <p>According to a company press release, Bixlenvo is described as the first STR option for virologically suppressed adults on complex HIV treatment regimens who are unable to take currently available STRs. The tablet combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor that the company says has no cross-resistance to other existing antiretrovirals. The combination of bictegravir and lenacapavir is not http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html Thu, 27 Aug 2026 17:47:22 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 in adults who are virologically suppressed.</p> <p>According to a company press release, Bixlenvo is described as the first STR option for virologically suppressed adults on complex HIV treatment regimens who are unable to take currently available STRs. The tablet combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor that the company says has no cross-resistance to other existing antiretrovirals. The combination of bictegravir and lenacapavir is not http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html Thu, 27 Aug 2026 17:47:22 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html <p>Gilead Sciences (Nasdaq: GILD) announced that the U.S. Food and Drug Administration has approved Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), a once-daily single tablet regimen (STR) for the treatment of HIV-1 in adults who are virologically suppressed.</p> <p>According to a company press release, Bixlenvo is described as the first STR option for virologically suppressed adults on complex HIV treatment regimens who are unable to take currently available STRs. The tablet combines bictegravir, an integrase strand transfer inhibitor, with lenacapavir, a capsid inhibitor that the company says has no cross-resistance to other existing antiretrovirals. The combination of bictegravir and lenacapavir is not http://www.streetinsider.com/FDA/FDA+approves+Gilead%27s+Bixlenvo+HIV+tablet+for+adults+on+complex+regimens/26991447.html Thu, 27 Aug 2026 17:47:22 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Press+Releases/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516 http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html <p class="bwalignc"> –<i> Novel Daily Oral Tablet Combines Bictegravir, a Guideline-Recommended INSTI with a High Barrier to Resistance, with Lenacapavir, a First-in-Class Capsid Inhibitor with No Cross-Resistance to Other Existing Antiretrovirals –</i> </p><p class="bwalignc"> –<i> Bixlenvo</i> <i>Now the Smallest STR; First and Only STR for Most People on Complex HIV Treatment Regimens </i>– </p> <p> FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg), the smallest once-daily single tablet regimen (STR) for the treatment of HIV in adults who are virologically suppressed. Bixlenvo is now the http://www.streetinsider.com/Business+Wire/U.S.+FDA+Approves+Gilead%E2%80%99s+Bixlenvo%E2%84%A2%2C+a+New+Once-Daily+Single+Tablet+Option+for+Virologically+Suppressed+Adults+With+HIV%2C+Including+Those+on+Complex+Regimens/26991444.html Thu, 27 Aug 2026 17:47:00 -0400 A.06822034 A.20820862 A.60012012 GILD O.00092067 O.05018046 O.20026344 O.20847516